글로벌 종양 용해 증후군 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 종양 용해 증후군 시장

종양 용해 증후군 시장은 2021-2028년 예측 기간에 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에서 언급한 예측 기간에 6%의 CAGR로 성장할 것으로 예측하여 시장을 분석합니다.

종양 용해 증후군(TLS)은 상당수의 암세포가 빠르게 파괴되고 대사 부산물이 혈류로 방출될 때 발생하는 대사 장애입니다. 이 증후군은 림프종, 백혈병 및 기타 형태의 종양과 같은 질병에 대한 1차 화학 요법을 받는 사람들에게 특히 흔합니다. 종양 용해 증후군은 간, 심장 및 신장을 비롯한 기타 장기에 손상을 입힙니다.

종양 용해 증후군의 유병률 증가와 노령 인구 증가는 시장 성장률에 영향을 미치는 주요 요인입니다. 또한, 새로운 치료법 및 치료 옵션과 관련된 발전, 증가하는 의료비 지출, 정부의 유리한 환불 정책은 종양 용해 증후군 시장을 확대할 요인입니다. 혈액암 발병률 증가와 암 및 기타 암 관련 질병을 치료하기 위한 공공 및 민간 기관의 지원을 포함한 다른 요인은 시장 성장률을 완화할 것입니다.

게다가, 연구 개발 활동의 증가와 신흥 시장은 2021~2028년 예측 기간 동안 종양 용해 증후군 시장에 유익한 기회를 제공할 것입니다.

그러나 높은 치료 비용과 종양 용해 증후군과 관련된 부작용은 시장 성장을 방해하는 요인입니다. TLS와 관련된 질병, 치료 및 합병증에 대한 인식 부족은 위에서 언급한 예측 기간 동안 종양 용해 증후군 시장에 더욱 큰 도전이 될 것입니다.

This tumor lysis syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tumor lysis syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Tumor Lysis Syndrome Market Scope and Market Size

The tumor lysis syndrome market is segmented on the basis of pathophysiology, causative therapy, diagnosis, drug type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of pathophysiology, the tumor lysis syndrome market is segmented into hyperuricemia, acute kidney injury and others.
• On the basis of causative therapy, the tumor lysis syndrome market is segmented into chemotherapy, radiation therapy, biological therapy and others.
• On the basis of diagnosis, the tumor lysis syndrome market is segmented into blood urea nitrogen test, creatinine test, serum electrolytes test and others.
• On the basis of drug type, the tumor lysis syndrome market is segmented into allopurinol, rasburicase, febuxostat and others.
• On the basis of route of administration, the tumor lysis syndrome market is segmented into oral, injectable and others.
• On the basis of end-users, the tumor lysis syndrome market is segmented into hospital, homecare, specialty clinics, and others.
• The tumor lysis syndrome market is also segmented on the basis of distribution channel into hospital pharmacy, online pharmacy, retail pharmacy and others.

Tumor Lysis Syndrome Market Country Level Analysis

Tumor lysis syndrome market is analyzed and market size information is provided by the country, pathophysiology, causative therapy, diagnosis, drug type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the tumor lysis syndrome market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the tumor lysis syndrome market due to the presence of major key players, increased R&D activities, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing medical tourism, rising prevalence of blood cancer and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Tumor lysis syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Tumor Lysis Syndrome Market Share Analysis

Tumor lysis syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to tumor lysis syndrome market research.

종양 용해 증후군 시장 보고서에서 다루는 주요 기업은 Johnson & Johnson Private Limited, Ironwood Pharmaceuticals, Inc., Sanofi, The Menarini Group, Merck KGaA, Takeda Pharmaceutical Company Limited, AstraZeneca, Hikma Pharmaceuticals PLC, Pfizer Inc., Lonza, Amgen Inc, Genentech, Inc., Ionis Pharmaceuticals, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Mallinckrodt, F. Hoffmann-La Roche Ltd 등 국내 및 글로벌 기업입니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-50421